'Causality assessment' presentation slideshows

Causality Assessment in Poisoning Essential for Data Quality

Causality Assessment in Poisoning Essential for Data Quality. Hugo Kupferschmidt, M.D. Director Swiss Toxicological Information Centre Zuerich. Seville, May 8, 2008 XXVIII EAPCCT Congress, Melia Sevilla. Overview. Definitions History Rationale

578 views • 39 slides

Kavita Gulati Department of Pharmacology Vallabhbhai Patel Chest Institute

Adverse drug reaction monitoring in patients of bronchial asthma and COPD with focus on methylxanthines. Kavita Gulati Department of Pharmacology Vallabhbhai Patel Chest Institute University of Delhi, Delhi-110007 SOPI-2010, LHMC, New Delhi, 27/11/2010,. Adverse Drug Reactions.

623 views • 34 slides

C AUSALITY A SSESSMENT OF R EPORTED A DVERSE D RUG R EACTIONS

Ana Filipa Macedo Faculty of Health Sciences Portugal. C AUSALITY A SSESSMENT OF R EPORTED A DVERSE D RUG R EACTIONS. No drug which is pharmacologically effective is entirely without hazard. Efficacy. Quality. Safety. Safety is a relative concept. H ISTORICAL P ERSPECTIVE.

245 views • 24 slides

Overview of Pediatric Safety Reporting and Role of the Committee Pediatric Advisory Committee Meeting March 22, 2006

Overview of Pediatric Safety Reporting and Role of the Committee Pediatric Advisory Committee Meeting March 22, 2006. Solomon Iyasu, M.D., M.P.H. Acting Deputy Director Division of Pediatric Drug Development Center for Drug Evaluation and Research Food and Drug Administration.

434 views • 17 slides

Cause-Effect Pair Challenge

177 views • 16 slides

PSUR as tool for signal detection

PSUR as tool for signal detection. Pauline H. Gerritsen-van Schieveen European Director Drug Safety and Pharmacovigilance. Objectives of the Presentation. To share the Astellas Pharma Europe R&D procedures for Risk Analysis in the PSUR process. PSURs as tool for signal detection.

380 views • 11 slides

Concept Paper #3: Risk Assessment of Observational Data Session 1: Good Pharmacovigilance Practices

Concept Paper #3: Risk Assessment of Observational Data Session 1: Good Pharmacovigilance Practices. Linda S. Hostelley on behalf of PhRMA. PhRMA Supports FDA Efforts on Risk Management Risk Management is a Continuum Positive Benefit Risk is Key Benefits and Risks Drive RMP

314 views • 7 slides